Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Tesa/Ipa
Add to protocol
Build with Tesamorelin + Ipamorelin
Compare prices
Pharmacies & vendors
Calculate dosing
Reconstitution
Pre-mixed blend of Tesamorelin (GHRH analog) and Ipamorelin (selective GHRP). An alternative to the CJC-1295/Ipamorelin combination, using the FDA-approved GHRH analog Tesamorelin for the GHRH-axis component.
Tesamorelin stimulates GH release via the GHRH receptor (same axis as CJC-1295 but with stronger clinical evidence for visceral fat reduction). Ipamorelin activates the ghrelin receptor for synergistic GH amplification.
Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy. The combination with Ipamorelin is a vendor-created formulation that leverages Tesamorelin's clinical evidence base with Ipamorelin's selective GH secretagogue properties.
Typical Dose
6-12mg Tesa + 2-4mg Ipa per vial
Frequency
Daily, typically evening
Route
SubQ
Notes
Various ratios: 6/2mg, 8/2mg, 10/3mg, 12/4mg. Lyophilized powder, reconstitute with bacteriostatic water. Store at 2-8°C.
Build a protocol with Tesamorelin + Ipamorelin, schedule blood work for key biomarkers, and track your results.
Build Protocol with Tesamorelin + IpamorelinThis platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs